Cleared Special

K212427 - cobas Cdiff nucleic acid test for use on the cobas Liat System (FDA 510(k) Clearance)

Oct 2021
Decision
77d
Days
Class 2
Risk

K212427 is an FDA 510(k) clearance for the cobas Cdiff nucleic acid test for use on the cobas Liat System. This device is classified as a C. Difficile Toxin Gene Amplification Assay (Class II - Special Controls, product code OZN).

Submitted by Roche Molecular Systems, Inc. (Pleasanton, US). The FDA issued a Cleared decision on October 20, 2021, 77 days after receiving the submission on August 4, 2021.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3130. Amplification Assay For The Detection Of C. Difficile Toxin Genes From Stool Specimens Of Symptomatic Patients..

Submission Details

510(k) Number K212427 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 04, 2021
Decision Date October 20, 2021
Days to Decision 77 days
Submission Type Special
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code OZN — C. Difficile Toxin Gene Amplification Assay
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3130
Definition Amplification Assay For The Detection Of C. Difficile Toxin Genes From Stool Specimens Of Symptomatic Patients.